People who live with narcolepsy — about one out of every 2,000 Americans — don’t have many options when it comes to treatment. The milder form of narcolepsy includes symptoms of excessive ...

Axsome Therapeutics, Inc. AXSM announced that the FDA has approved Symbravo (meloxicam and rizatriptan) for the acute ...

Agonists of gamma-aminobutyric acid (GABA B) receptors, which are indicated for the treatment of narcolepsy, currently represent more than $1.7 billion in annual sales in the United States.

Alkermes has shared positive topline data from the narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) cohorts of a Phase Ib study of ALKS 2680 as a potential once-daily treatment for narcolepsy.

AXSM stock is riding on upbeat preliminary 2024 results. The company's depression drug, Auvelity, drives its top line while ...

A narcolepsy service dog is a long term commitment. But having one can help you live a safer life by alerting you before a narcolepsy episode. They can also help with other daily tasks and provide ...

Harmony Biosciences' Wakix shows promise for significant revenue growth. Find out why HRMY stock’s profitability and pipeline ...

These two leading narcolepsy treatments will be added to our broad and growing CNS portfolio. We will leverage our specialisation and reach to grow these products in existing and new markets, thereby ...

Xywav is the only liquid medicine approved to treat both narcolepsy and idiopathic hypersomnia. which is safe and effective for adults. Parasomnias are disruptive sleep disorders that can occur ...

It was a huge relief to be diagnosed with narcolepsy, because I was able to finally say this is the problem. And this is what I need to resolve the problem. Treatment has been life-changing.

Alkermes wants to augment its pipeline with M&A or licensing deals in serious mental illnesses and substance abuse. “I think anyone who's developing a drug in these spaces, they are probably better ...